YDES · Why this verdict
Why YD Bio (YDES) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.1/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
YD Bio is a speculative biotech in a recovery attempt after a 73% drawdown, supported by insider buying and peer-leading growth but held back by weak momentum and a death cross.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Insiders bought $128,525 across 3 transactions in 90 days with no sales, giving a bullish signal. Insider | Insider net buying continues or institutions keep accumulating. | →Stable |
| CounterThe buying is only 0.027% of market cap, which is too small to signal strong conviction. | ||
The shares are attempting a recovery despite a death cross, with MACD improving and RSI at 72. Chart pattern detection | Price holds above the $6.26 stop level as the recovery extends. | →Stable |
| CounterAn RSI of 72 is overbought and the death cross is a hard block, so the rally may fade quickly. | ||
The company outperforms peers, ranking as an industry growth leader with a peer growth rank of 9.7 and conservative debt levels. Peer-rank breakdown | Peer growth rank stays above 8.0. | →Stable |
| CounterGrowth has no underlying data (confidence 0.5), so the rank may rest on thin inputs. | ||
Momentum at 4.0 is below the engine's 4.5 threshold, with falling on-balance volume despite an overbought RSI. Engine gate (failed) | Momentum score recovers above 4.5 as volume accumulation returns. | →Stable |
| CounterThe price sits above the 200-day average and MACD is positive, so the weak reading is driven mainly by volume. | ||
The stock is 73% off its 52-week high in a binary-outcome biotech industry, placing it in the speculative class. Suitability rationale | Drawdown from the 52-week high narrows below 50%. | →Stable |
| CounterStrong net margins of 25% and a healthy current ratio suggest the balance sheet can support the story. | ||
Insiders bought $128,525 across 3 transactions in 90 days with no sales, giving a bullish signal.
→StableInsider
- Expectation
- Insider net buying continues or institutions keep accumulating.
CounterThe buying is only 0.027% of market cap, which is too small to signal strong conviction.
The shares are attempting a recovery despite a death cross, with MACD improving and RSI at 72.
→StableChart pattern detection
- Expectation
- Price holds above the $6.26 stop level as the recovery extends.
CounterAn RSI of 72 is overbought and the death cross is a hard block, so the rally may fade quickly.
The company outperforms peers, ranking as an industry growth leader with a peer growth rank of 9.7 and conservative debt levels.
→StablePeer-rank breakdown
- Expectation
- Peer growth rank stays above 8.0.
CounterGrowth has no underlying data (confidence 0.5), so the rank may rest on thin inputs.
Momentum at 4.0 is below the engine's 4.5 threshold, with falling on-balance volume despite an overbought RSI.
→StableEngine gate (failed)
- Expectation
- Momentum score recovers above 4.5 as volume accumulation returns.
CounterThe price sits above the 200-day average and MACD is positive, so the weak reading is driven mainly by volume.
The stock is 73% off its 52-week high in a binary-outcome biotech industry, placing it in the speculative class.
→StableSuitability rationale
- Expectation
- Drawdown from the 52-week high narrows below 50%.
CounterStrong net margins of 25% and a healthy current ratio suggest the balance sheet can support the story.
Per-dimension breakdown
Quality
6.1/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 1.9 |
| Net margin | 10.0 |
| Current ratio | 7.8 |
| Moat | 6.5 |
| Piotroski F | 4.4 |
- ▸Strong margins: 25%
Growth
5.0/10data confidence 50%Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 1.5 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 7.5 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 5.0 |
Insider
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider buying — $128,525 (0.029% of mkt cap)
- ▸Institutions accumulating
Peer rank
7.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 7.2 |
| growth rank | 9.7 |
- ▸Industry growth leader
- ▸Conservative debt levels
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.7 |
| support resistance | 5.0 |
| 52w position | 0.0 |
Risk (lower is worse)
7.3/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 9.4 |
| days to cover | 10.0 |
| volatility | 0.0 |
| debt equity | 10.0 |
Catalyst
8.0/10data confidence 25%| Component | Sub-score |
|---|---|
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- DEATH_CROSS:momentum=6.5>=5.0 recovering
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 53 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -72% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.5>=5.5. Top dim: Catalyst at 8.0; weakest: Technical at 3.2. No conviction either direction.
The strongest dimensions are Catalyst at 8.0, Insider at 7.9, and Peer rank at 7.9; the weakest are Technical at 3.2, Sentiment at 5.0, and Growth at 5.0. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Insider Net Buying
Trip ifNet insider value over 90 days falls below $0 from current +$128,525.
- P2Recovery Despite Death Cross
Trip ifShare price falls below the $6.26 stop level from current $6.73.
- P3Peer Outperformance
Trip ifPeer growth rank falls below 6.0 from current 9.7.
- P4Momentum Below Threshold
Trip ifMomentum score rises above 4.5 from current 4.0.
- P5Speculative Binary Drawdown
Trip ifDrawdown from the 52-week high narrows to less than 50% from current 73%.